Medicina
Departament
Pau
Montesinos
Publicacions en què col·labora amb Pau Montesinos (32)
2024
2023
-
Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
Cancer Medicine, Vol. 12, Núm. 14, pp. 14892-14901
-
Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
Blood Cancer Journal, Vol. 13, Núm. 1
-
Genomics improves risk stratifi cation of adults with T-cell acute lymphoblastic leukemia enrolled in measurable residual disease-oriented trials
Haematologica, Vol. 108, Núm. 4, pp. 969-980
-
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
HemaSphere
-
Molecular Landscape and Validation of New Genomic Classification in 2668 Adult AML Patients: Real Life Data from the PETHEMA Registry
Cancers, Vol. 15, Núm. 2
2022
-
A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries
Blood Cancer Journal, Vol. 12, Núm. 7
-
Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry
Leukemia Research, Vol. 115
-
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Cancers, Vol. 14, Núm. 9
-
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
Cancers, Vol. 14, Núm. 11
-
Impact of FLT3–ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study
Cancers, Vol. 14, Núm. 23
-
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries
Leukemia, Vol. 36, Núm. 4, pp. 913-922
-
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study
Blood Advances, Vol. 6, Núm. 4, pp. 1278-1295
2021
-
Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?
Leukemia, Vol. 35, Núm. 6, pp. 1571-1585
-
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia
Leukemia, Vol. 35, Núm. 8, pp. 2358-2370
-
Outcomes and prognostic factors of adults with refractory or relapsed T-cell acute lymphoblastic leukemia included in measurable residual disease-oriented trials
Hematological Oncology, Vol. 39, Núm. 4, pp. 529-538
2020
-
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project
Haematologica, Vol. Online ahead of print
-
Obesity is a risk factor for acute promyelocytic leukemia: Evidence from population and cross-sectional studies and correlation with FLT3 mutations and polyunsaturated fatty acid metabolism
Haematologica, Vol. 105, Núm. 6, pp. 1559-1566
2019
-
An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens
Leukemia and Lymphoma, Vol. 60, Núm. 4, pp. 1030-1035
-
Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy
Leukemia and Lymphoma, Vol. 60, Núm. 5, pp. 1146-1155